BioAffinity Technologies (BIAF) announced a study with Brooke Army Medical Center to validate the clinical utility of using the CyPath Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer. “Clinicians who have patients scheduled to undergo diagnostic bronchoscopy have told us that CyPath Lung could be very helpful by providing an independent and complementary test for diagnosis,” said Gordon Downie, chief medical officer of BioAffinity Technologies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Highlights CyPath Lung Case Study in Diagnostics
- BioAffinity Technologies releases clinical case study on CyPath Lung test
- bioAffinity Highlights CyPath Lung Clinical Utility in Surveillance
- bioAffinity Technologies Updates Investor Presentation Materials Online
- bioAffinity Adds Leading Lung Cancer Experts to Advisory Board